366,492 Shares of Medtronic PLC $MDT Purchased by Mirae Asset Global Investments Co. Ltd.

Posted by Brian Himes on Nov 3rd, 2026

Mirae Asset Global Investments Co. Ltd. bought a new position in Medtronic PLC (NYSE:MDT – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 366,492 shares of the medical technology company’s stock, valued at approximately $31,625,000.

Other hedge funds also recently made changes to their positions in the company. Gradient Investments LLC lifted its position in Medtronic by 3.9% during the second quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company’s stock valued at $38,842,000 after purchasing an additional 18,509 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in shares of Medtronic by 14.8% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 149,708 shares of the medical technology company’s stock worth $12,918,000 after buying an additional 19,315 shares in the last quarter. Czech National Bank increased its holdings in shares of Medtronic by 4.7% in the 2nd quarter. Czech National Bank now owns 365,443 shares of the medical technology company’s stock worth $28,589,000 after buying an additional 16,292 shares during the last quarter. Congress Asset Management Co. bought a new stake in shares of Medtronic in the 3rd quarter worth about $76,201,000. Finally, Worth Asset Management LLC bought a new stake in shares of Medtronic in the 3rd quarter worth about $1,056,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on MDT. BTIG Research decreased their target price on shares of Medtronic from $100.00 to $99.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. Truist Financial reiterated a “hold” rating and issued a $99.00 price target (up from $86.00) on shares of Medtronic in a research report on Wednesday, September 2nd. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research note on Wednesday, October 14th. Stifel Nicolaus upped their price objective on Medtronic from $80.00 to $95.00 and gave the company a “hold” rating in a research report on Wednesday, September 2nd. Finally, Needham & Company LLC restated a “buy” rating on shares of Medtronic in a research report on Thursday, September 17th. Eighteen research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.88.

View Our Latest Research Report on MDT

Medtronic Trading Up 2.9%

Shares of MDT opened at $99.34 on Tuesday. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The company has a market cap of $127.08 billion, a P/E ratio of 24.47, a P/E/G ratio of 2.22 and a beta of 0.55. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The company’s fifty day simple moving average is $91.82 and its 200-day simple moving average is $88.36.

Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. The firm had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The firm’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, analysts expect that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were paid a $0.72 dividend. The ex-dividend date of this dividend was Friday, September 25th. This represents a $2.88 annualized dividend and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is presently 70.94%.

Insiders Place Their Bets

In other news, CEO Geoffrey Martha sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the transaction, the chief executive officer owned 277,866 shares of the company’s stock, valued at approximately $26,397,270. This represents a 15.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Marinaro sold 10,420 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the sale, the executive vice president owned 105,916 shares in the company, valued at approximately $10,167,936. The trade was a 8.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,903 shares of company stock valued at $5,889,203 over the last 90 days. Insiders own 0.27% of the company’s stock.

Medtronic Profile

(Free Report)

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.